FGFR4 and Klotho Polymorphisms not associated with CV outcomes in CKD: Study

To assess the clinical significance of these findings, Mendelian randomization research examined the correlation of FGFR4 and Klotho genetic variations with echocardiographic parameters and cardiac events in CKD patients. The prospective Cardiovascular and Renal Outcome in CKD 2–4 Patients–Fourth Homburg Evaluation research included 519 CKD G2–G4 patients, 519 of whom agreed to SNP genotyping (FGFR4: rs351855; Klotho: rs9536314). Echocardiographic tests at baseline and 5 years later were used to estimate the prevalence of LVH using the left-ventricular mass index (LVMI). For the major objectives of cardiac decompensation and atherosclerotic cardiovascular disease, patients were followed for 5.1 2.1 years (ASCVD).

Carriers of the various alleles did not vary in terms of baseline LVMI or LVMI changes between baseline and follow-up. One hundred and four individuals experienced cardiac decompensation, and 144 had ASCVD. The time to cardiac decompensation and ASCVD did not differ across allele carriers.

The findings of this investigation do not support a clinical function for either FGFR4 stimulation or soluble Klotho deficiency in the development of LVH added the authors in conclusion.

Reference:

Sellier A, B, Seiler-Mußler S, Emrich I, E, Böhm M, Fliser D, Zawada A, M, Heine G, H: FGFR4 and Klotho Polymorphisms Are Not Associated with Cardiovascular Outcomes in Chronic Kidney Disease. Am J Nephrol 2021. doi: 10.1159/000519274